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LETTER TO THE EDITOR
Surgical Management
of an Inoperable Giant
Pleomorphic
Rhabdomyosarcoma of
the Chest Wall
To the Editor:
A 65-year-old men was referred to
our hospital with a complaint of giant
mass on the chest wall, which reached
its present size to 3 cm in 5 months. On
physical examination, the mass was firm,
fixed, necrotized, and nontender (Figure
1). Metastatic lesions were detected in the
lung. An incisional biopsy of the tumor
confirmed the diagnosis of pleomorphic
rhabdomyosarcoma, 2 months ago in an-
other clinic. The patient was considered as
inoperable because the lung was meta-
static, and the mass excision was not
performed. Serous leakage, observed in
the incision area, was irritating for the
patient. The patient brought to our clinic
for the mass excision. The mass was
totally excised. The size of the tumor
was 16  16  15 cm, and the weight
was 1750 g. The chest wall and the
axillary skin defect were reconstructed
with a latissimus dorsi muscle flap. The
skin was primarily closed. After the op-
eration, the patient has received chemo-
therapy in an oncological center. The
postoperative course was uneventful,
and no recurrence was found. The pa-
tient is still alive after 6 months fol-
low-up and was satisfied from the opera-
tion. Surgical excision has not seemed to
contribute to the improvement in survival
after the mainstay of local disease control
on chest wall rhabdomyosarcoma.1 The
excision of giant tumors is usually not
preferred because of its hardness, and it
is useless for survival. Still, resection of
giant mass can improve the patient’s
condition and may provide a good qual-
ity of life.2
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Acute Renal Failure
in a Patient Receiving
Anti-VEGF Therapy for
Advanced Non-small
Cell Lung Cancer
To the Editor:
Bevacizumab, a monoclonal hybrid
antibody that binds to and neutralizes vas-
cular endothelial growth factor, has shown
promising efficacy in the adjunctive treat-
ment of patients with several cancers.
However, significant side effects are asso-
ciated with bevacizumab, especially hy-
pertention and proteinuria, but rarely acute
renal failure. Here, we report a 67-year-
old man, habitted smoker, who developed
new-onset acute renal failure after receiv-
ing bevacizumab for stage IV non-small
cell lung cancer. On January 16, 2008,
treatment with paclitaxel 300 mg (175
mg/m2), carboplatin 580 mg (AUC  6)
plus bevacizumab 900 mg (15 mg/kg)
intravenously every 3 weeks was initiated.
During the first two cycles, the patient’s
serum creatinine was stable at approxi-
mately 76 mol/liter and urinalysis was
unremarkable. On March 2, 2008, his se-
rum creatinine level was 461 mol/liter.
Then he had a progressive increase in
creatinine levels and became oliguric re-
quiring intermittent hemodialysis. Dys-
morphic red blood cells and a few coarse
granular casts were presented in the urine
sediment. Twenty-four hour urine total
protein was 9.47 g. So, the scheduled third
cycle was withheld. Other laboratory tests
including liver function, coagulation sta-
tus, autoimmune antibodies, etc. showed
normal. Kidney ultrasound showed en-
hanced echo signal in cortex area and
normal sized kidneys with no hydrone-
phrosis. Renal vessels were normal. For-
tunately, the patient’s renal function con-
tinued to improve and dialysis was no
longer required. And the treatment for
non-small cell lung cancer was changed to
Gefitinib 250 mg once per day because of
PD proven by computed tomography. An
ultrasound-guided renal biopsy was de-
layed until the patient became more clin-
ically stable. In kidney biopsy, glomeruli
were characterized by intense glomerular
hypercellularity. Much of this hypercellu-
larity was mesangial and segmental
endothelial proliferation, giving the
glomerular tuft a ‘lobular’ appearance
(Figure 1A). The glomerular basement
membrane thickening with the appear-
ance of double contours was caused by
mesangial cell and mesangial matrix
interposition into the subendothelial
zone of the capillary loops, which
caused capillary loops narrow and oc-
cluded (Figure 1B). Immuno-fluores-
cence microscopy showed bright dif-
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FIGURE 1. Giant mass on the left axil-
lary and thorax wall.
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fuse granular glomerular capillary
wall and mesangial staining for C3
(Figure 1C), but others were negative.
In electron microscopy examination,
there was mesangial hypercellularity
and increased mesangial matrix, which
were obviously inserted into subendo-
thelium. The electron dense deposited
in mesangial and subendothelial area
and the glomerular basement mem-
brane was thickened diffusely. Few
dense deposits were presented in sub-
epithelial region. Segmental foot pro-
cess effacement was observed (Figure
1D). The final kidney biopsy findings
were interpreted as type III mem-
branoproliferative glomerulonephritis.
To our surprise, at discharge on April
3, 2008, his serum creatinine stabi-
lized at 107 mol/liter and urinalysis
showed normal. In an 8-month follow-
up, the patient’s renal function was
still normal.
The nephrotoxicity encountered
here was more likely secondary to bev-
acizumab and not to concomitant pacli-
taxel treatment in the absence of evi-
dence of a prior association with this
agent. Carboplatin administration could
lead to renal impairment but was fre-
quently associated with tubular dysfunc-
tion.1 Other potential causes of acute
renal failure were excluded. The patho-
genesis of bevacizumab-associated renal
toxicities was still unclear. Some pro-
posed mechanisms of bevacizumab in-
cluded the following. (1) Secondary to
hypertension. (2) Human and animal
data suggested that appropriate vascular
endothelial growth factor expression in
the kidney was important to maintain
the structure and function of the glo-
merulus. So, bevacizumab may cause
an alteration in vascular endothelial
growth factor expression through its
on-target effects and lead to endothe-
lial cell dysfunction and promote glomer-
ular disease.2 (3) Bevacizumab stimulated
antibody production, which leaded to
circulating immune complexes or in-
jury to glomerular structures. The
membranoproliferative glomerulone-
phritis picture on biopsy in our patient
suggested that stimulated antibody
production that, in turn, leaded to an-
tigen-antibody complex-mediated glo-
merulonephritis. (4) Bevacizumab was
a kind of protein so it could lead to
allergic reaction and induced intersti-
tial nephritis.3
As we know, only 12 renal bi-
opsy findings were published.2–7 Th-
rombotic microangiopathy was the
main pathologic type, which presented
in seven cases and other pathologic
types could also be found including
two cases of immune-complex-medi-
ated glomerulonephritis, one case of
cryoglobulinemic glomerulonephritis,
one case of focal segmental glomeru-
lar sclerosis, one case of interstitial
nephritis, and our case of membrano-
proliferative glomerulonephritis.
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FIGURE 1. A, The mesangial matrix increase was more severe in peripheral areas
of the tuft, giving the glomerular tuft a “lobular” appearance. B, Basement mem-
brane thickening was due to mesangial cell interposition along the subendothelial
area with consequent neoformation of basement membrane that gave the mor-
phologic aspect of “double contour.” C, It showed bright diffuse granular glomer-
ular capillary wall and mesangial staining for C3. D, The image showed the con-
comitant presence of subendothelial and subepithelial deposits. A mesangial cell
migrated to the subendothelial side of the lamina densa.
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Long-Term Follow-Up
of Severe Dysplasia and
Carcinoma In Situ of
the Bronchus
To the Editor:
In a previous issue of the journal,
Banerjee1 brilliantly reviewed the
available data from the literature about
the natural history of bronchial prein-
vasive lesions. We congratulate the
author for this very important and dif-
ficult work.
In his review, the author cited our
work published in the American Journal
of Respiratory and Critical Care Medicine
in 20012 that described the 24 months
follow-up of 416 preinvasive lesions in
104 patients. Indeed, we agree with the
author’s conclusions that limited individ-
ual lesion follow-up in most studies, as
well as interferences with local or even
systemic treatments, complicate the as-
sessment of the potential aggressiveness
of lesions known to be characterized by a
long carcinogenesis process.
In a recent published work, not
cited in Banerjee’s review, we provided
some answers to these limitations3 in
studying the long-term evolution of 37
patients and 54 high-grade preinvasive
lesions—31 carcinoma in situ (CIS) and
23 severe dysplasia (SD)—during a 12-
year period. Our study was performed
using auto-fluorescence bronchoscopy
with repeated bronchial biopsy sam-
pling over time, with a mean of seven
biopsies per individual lesion during
the follow-up and molecular analysis
of the baseline lesions. We believe that
this very long monitoring authorizes to
draw reliable conclusions on the ag-
gressiveness of high-grade lesions, de-
spite the fact that conservative endo-
bronchial treatment was applied to
persisting or relapsing lesions.
To reliably identify the factors that
are linked to the lesions’ evolution over
time, we used a very restrictive definition
of “progression,” including local progres-
sion to invasive cancer. We also defined a
locally treated lesion as “treatment resis-
tant” that recurred at any time during the
monitoring period and “treatment sensi-
tive” those that did not reoccur after local
treatment, whereas regressing lesions
were those that spontaneously disappeared
without treatment. This allowed us to clas-
sify accurately the more aggressive lesions
in the progression or treatment resistant
groups, while ascertaining that the spon-
taneously regressing lesions were truly be-
nign ones (Table 1).
In this study, we observed that all
the lesions that progressed to invasive
cancer were initially classified as CIS (7
of 7) according to World Health Orga-
nization 1999 standards,4 and 10 of 31
CIS were resistant to several courses of
endoscopic treatments, whereas 10 of 31
CIS were treatment sensitive and only 4
of 31 CIS spontaneously regressed with-
out recurrence during follow-up. Our
study also provided valuable informa-
tion on long-term SD and CIS patients
outcome, with, at the study end point,
nine deaths attributable to lung cancer
including four deaths directly related to
the progression of the initial high-grade
bronchial lesion. In addition, using care-
ful laser microdissection and robust mo-
lecular analysis on the baseline le-
sions,3,5 we could demonstrate that
losses of heterozygosity (LOH) of chro-
mosome 3p and 9p are significantly
more frequent in CIS compared with
SD, whereas 3p LOH seems to be a
strong predictor of progression in the
whole group of lesions and in the CIS
group (Table 1).
Altogether, our results lend strong
support to the World Health Organization
classification for the premalignant bron-
chial lesions, which clearly differentiates
CIS from SD,4 not only in confirming
their different outcomes, as we had previ-
ously observed,2 but also in providing ev-
idence of significant differences at the mo-
lecular level.
Finally, our contribution shows
that CIS histology as defined by 1999
WHO classification and the molecular
analysis of 3p LOH are useful indicators
of the evolution of high-grade preinva-
sive bronchial lesions. The molecular
analysis could easily be integrated in the
management decision tree of CIS and
SD of the bronchial epithelium.
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TABLE 1. Outcome of Bronchial Severe Dysplasia and Carcinoma In Situ
According to the Molecular Analysis of the Lesion at Baseline
Progression to
Invasive Cancer Tt R Tt S Regression P
Lesions with at
least one LOH
7/7 10/11 13/17 9/19 0.01a
3p LOH 6/6 7/11 6/16 2/17 0.0001b
5q LOH 3/5 3/10 1/15 5/17 0.09b
9p LOH 5/7 6/9 10/15 5/15 0.20b
a 2 test.
b Fisher’s exact test.
Tt R, treatment resistant; Tt S, treatment sensitive; LOH, loss of heterozygosity.
Modified from Am J Respir Crit Care Med. 2008;177:880–886.
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